Lead Product(s): Burixafor
Therapeutic Area: Immunology Product Name: TG-0054
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: GPCR Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 09, 2020
Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide.